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Abstract
The importance of proper lysosomal activity in cell and tissue homeostasis is underlined by ‘‘experiments of nature’’, i.e. genetic defects
in one of the at least 40 lysosomal enzymes/proteins present in the human cell. The complete lack of 1-4 a-glucosidase (glycogen storage
disease type II (GSD II) or Pompe disease) is life-threatening. Patients suffering from GSD II commonly die before the age of 2 years because
of cardiorespiratory insufficiency. Striated muscle cells appear to be particularly vulnerable in GSD II. The high cytoplasmic glycogen
content in muscle cells most likely gives rise to a high rate of glycogen engulfment by the lysosomes. The polysaccharides become
subsequently trapped in these organelles when 1-4 a-glucosidase activity is absent. During the course of the disease, muscle wasting occurs.
It is hypothesised that the gradual loss of muscle mass is caused by a combination of disuse atrophy and lipofuscine-mediated apoptosis of
myocytes. Moreover, we hypothesise that in the remaining skeletal muscle cells, longitudinal transmission of force is hampered by swollen
lysosomes, clustering of non-contractile material and focal regions with degraded contractile proteins, which results in muscle weakness.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Lysosomal storage diseases are a group of inborn meta-
bolic disorders characterised by accumulation of non-metab-
olised material inside lysosomes. In the majority of these
diseases the pathology is severe, leading to disabilities and
often to death. In general, each of the approximately 40
lysosomal enzymes can be affected by a genetic defect [1–3].
Table 1 provides an overview of lysosomal enzymes cur-
rently known and of pathological conditions due to impaired
synthesis and/or activity.
In one of the most frequently occurring lysosomal storage
diseases, i.e. lysosomal glycogen storage disease type II
(GSD II), muscle tissue is primarily affected. The hallmarks
of this syndrome are skeletal muscle weakness and hyper-
trophy of the heart as described for the first time in 1932 by
the Dutch physician Pompe [4]. In 1963, it was convincingly
shown that GSD II is caused by deficiency of the enzyme acid
1-4 a-glucosidase (EC 3.2.1.20) [5]. This defect results in
accumulation of glycogen inside the lysosome in a variety of
tissues including smooth and striated muscle. As both heart
and skeletal muscle are functionally affected, patients even-
tually suffer from cardiorespiratory failure [6]. The pace of
progression of this disease is primarily determined by the
residual activity of acid 1-4 a-glucosidase. Patients with a
complete lack of enzyme activity die before they are 2 years
old [7]. In contrast, patients with more than 25% residual
activity hardly show clinical symptoms [8]. The frequency of
the various forms of GSD II is estimated to be 1 out of 40,000
births [9].
In this review, attention will be paid to the structure and
function of lysosomes in general, to the assembly of
lysosomes and the synthesis of lysosomal enzymes, and
to the biological activity of lysosomes. Moreover, lysoso-
mal storage disease as a consequence of a genetic defect
will be discussed, with special emphasis on GSD II.
Finally, a novel hypothesis will be presented explaining
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the impairment of muscle mechanical function of patients
suffering from GSD II.
2. Structure and function of lysosomes
Lysosomes are organelles originating from the endo-
plasmatic reticulum [10]. Usually, the diameter of a
mature lysosome varies from 400 to 500 nm. The lyso-
somal membrane consists of a phospholipid bilayer that
envelops an acidic environment (pH 4–5) in which at
least 40 enzymes/proteins are active. To avoid autolysis of
the lysosomal membrane, the internal side of the membrane
is protected by various forms of lysosome-associated
membrane proteins (LAMPs), which contain numerous
sialic acid-rich oligosaccharides [11,12]. Vacuolar (H+)-
ATPases maintain the low internal pH of the lysosomes
[13].
The main function of the lysosomal system is to
engulf and subsequently digest macromolecules. In gen-
eral, these are either damaged or non-functional com-
pounds from endogenous origin, or exogenous substances
and microorganisms that penetrated the cell membrane.
Each of the lysosomal enzymes is able to break a
specific chemical bond of the engulfed material. Although
spatial separation of metabolic activity within the lyso-
somes is most likely absent, it is believed that the
lysosomal enzymes are able to coagulate to form enzyme
hypercomplexes that effectively degrade the internalised
macromolecules [14]. The degradation products are
actively or passively transferred back from the lysosomal
interior into the cytoplasm, and can be re-utilised for the
synthesis of functional molecules. Recent studies indicate
that LAMPs might also be involved in the transport of
lysosomal degradation products through the lysosomal
membrane [11]. It is tempting to speculate that in the
phagocytic process some macromolecules, such as cyto-
plasmic glycogen, are inadvertently engulfed by the
lysosome. To get rid of this ‘by catch’, the polysacchar-
ides have to be hydrolysed by acid 1-4 a-glucosidase and
the glucose molecules produced must be transported back
into the cytoplasm, most likely by the facilitating action
of LAMP2 [15].
Initially, it was assumed that lysosomes were largely
involved in the hydrolysis of tissue proteins [16]. How-
ever, in the last decade, several studies have provided
evidence that the cytoplasmic ubiquitin proteasome
system also substantially contributes to the degradation
of contractile and cytoskeletal proteins in muscle tissue
[17–23]. There are indications that lysosomes are
preferentially involved in the degradation of mitochon-
drial and sarcolemmal proteins, and in the process of
membrane turnover [24,25]. In addition, ligand/receptor
uncoupling is accomplished by engulfment of the
entire complex and subsequent intra-lysosomal proteol-
ysis [26].
Table 1
Lysosomal enzymes and related storage diseases
Lysosomal enzyme Disease
Lipid metabolism
Cathepsin A galactosialidosis
h-Galactosidase GM1-gangliosialidosis (Landing)
Hexosaminidase A
and B (h-chain)
GM2-gangliosialidosis (Sandhoff)
Hexosaminidase A
and S (a-chain)
GM2-gangliosialidosis
(Tay–Sachs)
h-Galactocerebrosidase galactocerebrosidosis (Krabbe)
Glucocerebrosidase glucocerebrosidosis (Gaucher)
Sphingomyelinase sphingomyelin lipidosis
(Niemann–Pick A, B)
Acid lipase cholesteryl ester storage disease
(Wolman)
Arylsulfatase A metachromatic leukodystrophy
a-Galactosidase A Fabry
Glycoprotein metabolism
Aspartylglucosaminidase aspartylglucosaminuria
a-L-Fucosidase fucosidosis
a-N-acetylneuraminidase sialidosis/mucolipidosis I
a-N-acetylgalactosaminidase Schindler disease
h-Galactosidase galactosialidosis
a-Neuraminidase galactosialidosis
a-Mannosidase a-mannosidosis
h-Mannosidase h-mannosidosis
Mucopolysaccharide metabolism
a-L-Iduronidase MPS I (Hurler/Scheie)
Iduronate-sulfate sulfatase MPS II (Hunter)
Heparansulfate sulfatase MPS IIIA (Sanfilippo A)
N-acetyl-a-D-glucosaminidase MPS IIIB (Sanfilippo B)
Acetyl transferase MPS IIIC (Sanfilippo C)
a-N-acetylglucosamine
6-sulfatase
MPS IIID (Sanfilippo D)
N-acetylgalactosamidase-6-sulfate
sulfatase
MPS IV (Morquio A)
h-Galactosidase MPS IVB (Morquio B)
Arylsulfatase B MPS VI (Maroteaux–Lamy)
h-Glucuronidase MPS VII (Sly)
Various lysosomal functions
Acid 1-4 a-glucosidase glycogenosis type II (Pompe)
Cathepsin K pycnodysostosis
Prosaposin (sphingolipid activator) complex lipidosis
GM2 activator (sap3) GM2-gangliosialidosis/AMB
variant
Palmitoyl-protein thioesterase infantile neuronal ceroid
lipofuscinosis
Pepstatin-insensitive peptidase juvenile neuronal ceroid
lipofuscinosis
(Deficient) cholesterol recycling cholesterollipidosis
(Niemann–Pick C)
Other lysosomal enzymes
Acid phosphatase (LAP) no pathology described in humans
Cathepsin B no pathology described in humans
Cathepsin D no pathology described in humans
Cathepsin L no pathology described in humans
Tartrate-resistant acid
phosphatase (TRAP)
no pathology described in humans
Based on Gieselmann [1] Bijvoet [71] and Michalski and Klein [79].
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3. Lysosome assembly
Like any cellular structure, the assembly of lysosomes
starts with the transcription of genes encoding their specific
proteins. Transcription of genes and translation of mRNA
encoding for the different lysosomal enzymes is inherently
complex [27–29]. Most of the lysosomal genes described so
far lack the specific TATA and CAAT motifs adjacent to the
transcription start site. The absence of these motives in the
promoter region is characteristic for mammalian ‘‘house-
keeping’’ genes [30]. The expression of the individual
lysosomal enzymes is not mutually linked, and the lysoso-
mal content of distinct enzymes may differ between tissues
and metabolic situations [31]. Information on the regulatory
mechanisms underlying lysosomal protein expression is still
very fragmented, but points towards a multitude of factors
that are able to influence gene transcription and mRNA
translation of the distinct lysosomal enzymes [28,32–35].
These include, among others, hormones (e.g. growth hor-
mone and insulin) and metabolically challenging situations
such as starvation [36].
Though the precise regulation of gene expression of
lysosomal proteins is still incompletely understood, detailed
information on post-translational handling of lysosomal
enzymes is available [37–39]. Precursors of lysosomal
enzymes are synthesised in the cytoplasm at the endoplas-
matic reticulum. Substantial post-translational modification
occurs in subsequent steps required for the transport of
(pro)enzymes to the lysosomes. Maturation of the precur-
sors of lysosomal enzymes involves processes in the endo-
plasmatic reticulum and the Golgi complex, where protein
folding and chemical modification through the addition of
carbohydrate chains (i.e. attachment of mannose 6-phos-
phate (M6P) groups) take place. These M6P groups are in
the trans-Golgi network recognized by M6P receptors and
subsequently bound. These receptor/ligand complexes are
packaged into clathrin-coated vesicles that fuse with endo-
somes, where the ligand is released. The M6P receptor
returns to either the trans-Golgi network or the cell surface.
To avoid autolysis, lysosomal pro-enzymes usually contain
a pro-peptide region, i.e. a polypeptide chain that blocks
their active site as long as the enzyme is not transferred into
the lysosome. In general, the abovementioned polypeptide
chain is removed by proteolytic processing by cathepsins.
This step subsequently results in the activation of the
lysosomal enzyme.
4. Biological activity of lysosomes
Lysosomes are present in all eukaryotic cells. Their
specific activity appears to differ between tissues and
species, and is age-dependent [40]. In spleen and liver,
lysosomal activity is reported to be high, in differentiated
muscle tissue it is low [12]. During cellular differentiation,
lysosomes appear to be of importance, as the activity of at
least a number of lysosomal enzymes is increased in differ-
entiating tissue [41]. Moreover, the activity of lysosomal
enzymes, particularly the cathepsins, is high during devel-
opment of muscle tissue [42], while during ageing the
activity diminishes [40].
Whereas the activity of the lysosomal system differs
between tissues, it also depends on the metabolic status of
the organ or organism. Several stimuli have been identified
that regulate lysosomal activity, none of which however is
exclusively targeting the lysosome. In starvation and other
catabolic situations, the activity of lysosomal enzymes in the
muscle, especially cathepsin-L, is increased [43,44]. This
resulted in enhanced proteolysis, most likely due to an
increased lysosomal contribution to protein degradation
[43,44]. In inflammation, cancer cachexia, hyperthyroidism
and various neuromuscular disorders the activity of a
selected number of lysosomal enzymes was found to be
increased as well [16,45–49]. A variety of hormonal stimuli
(e.g. insulin, growth hormone, catecholamines, and clenbu-
terol) are exerting a negative effect on lysosomal activity
[48,50]. Experimental studies have revealed that pharmaco-
logical agents are able to decrease the activity of the
lysosomal system in vitro [51–54].
Due to the complexity of the system, it is comprehensible
that the majority of factors capable of influencing lysosomal
activity have not yet been fully identified. In the cases
mentioned above, little information is available on the
cellular signalling pathway through which lysosomal activ-
ity is modulated. Moreover, it is not clear whether the
observed changes in activity could be ascribed to an altered
number of lysosomes in the cells or to a specific change in
the activity of the lysosomal enzymes under investigation.
5. Common features in lysosomal storage diseases
Lysosomal storage diseases comprise a group of over 30
different syndromes. Commonly a division in lipidoses,
mucopolysaccharidoses and disorders of glycoprotein deg-
radation is made (Table 1). The common denominator of
these syndromes is a deficiency of one lysosomal enzyme/
protein, usually the result of a genetic disorder. If either an
enzyme or a transport protein is affected, progressive
accumulation of the corresponding, non-metabolized sub-
strate within the lysosome occurs. The lack of activity is
usually generalised, and accumulation of material is
observed in lysosomes of all tissues.
The consequences of the lack of activity of one specific
lysosomal enzyme on the overall lysosomal function is only
partially understood. Commonly, the dimensions of the
lysosomes appreciably increase in lysosomal storage syn-
dromes [55]. While the volume increases, the intra-lysoso-
mal pH must be kept low to ensure proper function of the
lysosomal enzymes. However, it is unlikely that the proton
pumps in the lysosomal membrane are able to entirely cope
with a substantial increase in lysosomal volume [56]. This
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may imply that in lysosomal storage diseases, lysosomal pH
gradually rises and that the actual activity of originally
unaffected lysosomal enzymes declines with the progression
of the disease.
As indicated in more detail above, the formation of
lysosomes is a complex process which involves a number
of steps (transcription, translation, trafficking of primary
proteins, post-translational modification). Therefore, the
molecular origin of the lysosomal dysfunction can differ
even within a particular storage syndrome. In GSD II, for
instance, over 40 polymorphisms are described [57]. In the
majority of lysosomal storage disorders the relationship
between genotype and phenotype is poorly understood.
Almost all lysosomal storage diseases show an appreciable
variability in clinical progression, and the onset and pro-
gression of symptoms vary with the residual activity of the
affected enzyme. In many lysosomal storage diseases, a
distinction in a severe infantile, an intermediate juvenile and
a mild adult form is made. This classification is somewhat
arbitrary as it represents a continuum of clinical severity,
and it is safe to assume that the accumulation of undigested
material already starts during the fetal stage in all patients.
A common feature observed in lysosomal storage dis-
orders is the formation of lamellar, roundly shaped electron
dense structures within cells. These structures are indicated
by a variety of names such as ceroid, myelin figures,
electron dense bodies or lipofuscin. Since lipofuscin accu-
mulation is typical in lysosomal storage disorders, the
mechanism underlying and the functional consequences of
lipofuscin formation are discussed in more detail below.
6. Mechanisms underlying lipofuscin formation
Lipofuscin is formed in the lysosomes, most likely after
peroxidation of autophagocytized material [58]. The chan-
ces that this material becomes peroxidized in the free
radical-rich environment of the lysosome rise when the
amount of undigested material and/or its dwelling time
inside the lysosome increase. In lysosomal storage diseases,
the size of the lysosomes can increase several fold as a result
of accumulation of undigested material. In addition, osmotic
swelling might occur. In case of lysosomal glycogen stor-
age, the hygroscopic properties of glycogen will also
promote lysosomal swelling. As indicated above, swelling
of lysosomes most likely increase the intra-lysosomal pH
when the proton pumps in the lysosomal membrane fail to
maintain the H+ gradient over the membrane [59]. Since
lysosomal enzymes are less active at elevated pH, passage
time of the engulfed material will increase. This in turn most
likely leads to increased formation and deposition of lip-
ofuscin. In tissue with a high cell turnover, enhanced
deposition of lipofuscin may not harm the cell, as the cells
are most likely removed before lipofuscin accumulation
becomes detrimental. In tissues with a relatively stable cell
population such as liver, muscle and nerve tissue, lysosomal
lipofuscin formation might exert large effects. As the
regenerative capacity of these tissues is relatively limited,
damaged cells are not, or not in sufficient numbers, replaced
in time. This consideration may explain why, despite the
fact that the lysosomal dysfunction is usually generalised,
the pathological features are most prominent in tissues with
relatively stable cell populations.
Experiments exploring the effect of a decline in lysoso-
mal activity have been performed in a variety of cultured
cell types [52,54,60,61]. In all experiments where lysosomal
activity was diminished, cells rapidly develop an abnormal
appearance. In general, lipofuscin accumulation is a com-
mon and prominent feature. It is of interest to note that in
senescent cells, where lysosomal activity also declines,
lipofuscin accumulation becomes apparent as a typical
feature of physiological ageing [62,63].
7. Putative functional consequences of lipofuscin
accumulation
Though the pathological significance of accumulation of
lipofuscin in the cells is not fully understood, several studies
strongly suggest that cellular accumulation of this material
is a trigger for cell death [64–66]. Nakae et al. [67] found a
significant correlation between lipofuscin accumulation and
apoptosis in the diaphragm muscle of mdx mice, a well-
established model for Duchenne muscle dystrophy. They
hypothesised that lipofuscin accumulation was caused by
elevated oxidative stress. Since satellite cells in the dia-
phragm of mdx mice also showed lipofuscin granules as
well as apoptosis, it was concluded that the regenerative
capacity of the diaphragm muscle was severely depressed.
As a consequence, overall diaphragm function is impaired,
which might eventually cause respiratory insufficiency.
As tissue degeneration readily occurs in lysosomal stor-
age diseases, the question remains whether the cells become
jeopardised due to improper functioning of the lysosomal
system in general, or due to cellular accumulation of lip-
ofuscin in particular. Since exposure to mild oxidative stress
triggers lipofuscin formation, this experimental condition
can be used to discriminate between these two options. The
mortality rate both of cells with blocked lysosomal function
and of cells exposed to mild oxidative stress was found to be
high. This finding might suggest that accumulation of lip-
ofuscin rather than improper functioning of the lysosomes
per se causes cell death.
It has been shown that accumulation of lipofuscin is
reversible, when the extent of accumulation is relatively
small, and lysosomal function is restored in due time [68].
Since the mortality rates of the rescued cells returned to
normal, these findings may have important clinical impli-
cations. It can be inferred that therapies aiming to restore
proper lysosomal function, such as enzyme replacement
therapy, should be started before a critical amount of lip-
ofuscin has been accumulated in the affected cell.
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8. Muscular dysfunction in GSD II
GSD II is the result of a genetic defect in the acid 1-4 a-
glucosidase gene resulting in an insufficient degradation of
glycogen inside the lysosomes. From an energetic point of
view, the amount of glycogen accumulating within the
lysosomes is inconsequential. It is unlikely that it creates a
shortage of glucose required for glycolytic and oxidative
energy conversion. This notion is supported by the obser-
vation that the muscle content of high-energy phosphates in
an experimental knockout mouse model for GSD II was
equal to that in non-affected controls [69].
As the genetic defect is generalised, the question remains
why particular muscular tissues are severely affected in
GSD II. A major cause is most likely the high concentration
of glycogen in the cytoplasm of cardiac and skeletal muscle
cells. As pointed out above, cytoplasmic glycogen is most
likely inadvertently engulfed by the lysosome and, hence,
lysosomal sequestration of this carbohydrate is most pro-
nounced in muscle cells when 1-4 a-glucosidase activity is
impaired. Since hepatocytes also contain relatively high
levels of cytoplasmic glycogen it is of interest to note that
despite the fact that glycogen accumulates in hepatic lyso-
somes to the same extent as in myocytes [6], patients suffer
from muscular insufficiency rather than from liver malfunc-
tion in GSD II.
Both clinical studies in GSD II patients [70] and exper-
imental investigations in 1-4 a-glucosidase null mice
(AGLU /) [71] show that impaired muscle function is a
prominent feature of this disease. Developed force by hind
limb muscles of AGLU / mice fell by approximately 50%
when the animals reached the age of 18 months [69]. This
decline in mechanical function could be partially explained
by loss of muscular mass. Compared to age-matched con-
trols, the wet weight of the hind limb muscle was on the
order of 25% less in AGLU / mice. The precise cause of
muscle wasting in GSD II is unknown, but one may
speculate that lipofuscin-mediated apoptosis contributes to
this process. Recent findings in AGLU / mice are in
support of this notion. In regions of the affected muscle cell
with marked lipofuscin deposits, nuclei with typical apop-
totic features were readily observed (Hesselink, unpublished
findings). Under normal conditions, these regions could
regenerate by the action of satellite cells [72,73], but in
GSD II, satellite cells may be affected as well. In this
respect, it is worth to mention that in the diaphragm of
mdx mice, the presence of lipofuscin precipitates was
associated with satellite cell apoptosis and, hence, a sub-
stantial decline in regenerative capacity [74]. If a similar
process occurs in satellite cells in GSD II patients and
AGLU / mice, muscle wasting is inevitable.
Since the loss of skeletal muscle mass cannot fully
account for the decline in muscular developed force [69],
additional factors exerting a negative effect on mechanical
performance should be considered. Recently, we hypothes-
ised that direct mechanical effects of the non-contractile
inclusions impair muscle strength [69]. Even in the early
stages of GSD II, lysosomal volume is substantially
increased. These swollen lysosomes (Fig. 1) disturb the
highly organized architecture of the contractile machinery
by interruption of myofibrils. Lysosomes do not contribute
to the generation of force and are unlikely to be attached to
Fig. 1. Muscle fiber of an AGLU / mouse in an advanced stage of GSD II. Arrows indicate swollen lysosomes.
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the contractile machinery. Therefore, shortening of sarco-
meres of the interrupted myofibrils near the site of inter-
ruption is likely to occur. As force can be transmitted from
interrupted to non-interrupted myofibrils by shearing, elon-
gation of sarcomeres of the non-interrupted myofibrils
adjacent to the lysosome will occur at the same time. This
will decrease the total force of a bundle of myofibrils
centred around an inclusion because inhomogeneities in
sarcomere length develop during contraction. These inho-
mogeneities diminish the force generating capacity of the
entire bundle.
By means of a recently developed numerical model of
contracting muscle which makes use of the Finite Element
Method [75], the loss of mechanical performance was
calculated as a function of the volume density of glyco-
gen-filled lysosomes. At a density of 15%, reflecting the
situation in muscles of 12-month-old AGLU / mice, the
loss in mechanical performance was calculated to be about
25% (Drost, unpublished results). This implies that about
half of the observed loss in muscle function may be caused
by hampering of mechanical activity by the swollen lyso-
somes.
When GSD II progresses, deposits of extra-lysosomal
material also become apparent in the affected muscle cells
(Fig. 1) [76,77]. Electron microscopical analysis revealed
that at the borders of the large inclusions, degradation of
myofibrillar material occurred and that degraded myofibrils
were often present inside these inclusions. This focal
myofibrillar degradation will directly affect mechanical
performance.
In more progressed stages of GSD II, short cell segments
show degeneration over their entire cross-section. Apoptotic
nuclei are present in these regions and the contractile
material is in complete disarray while the basal membrane
remains intact. In this situation, force is most likely trans-
mitted to adjacent cells. Though cell to cell transmission of
forces has been shown to be very effective in healthy
muscles [78] it remains to be seen whether this is also the
case in muscles of which most fibres are structurally in
disarray.
Although all striated muscles are affected, the decline in
mechanical function in cardiac and respiratory muscle is
most life threatening. In the clinical situation, patients
suffering from a complete lack of 1-4 a-glucosidase activity
commonly die before the age of 2 years, because of
cardiorespiratory insufficiency. In the past, all therapeutic
measures to relieve the severity of the disease failed. Very
recently, a breakthrough was reached by treatment of a
limited number of very young patients with recombinant
human 1-4 a-glucosidase [70]. In the two youngest of the
four children included in the study at an early stage of their
disease, clinical signs of GSD II remained absent and
patients showed a normal development after treatment with
recombinant human 1-4 a-glucosidase [70].
In summary, a brief overview has been provided on the
structure, assembly and biological function of lysosomes.
Special attention was paid to one particular kind of lysoso-
mal dysfunction due to a genetic defect, i.e. 1-4 a-glucosi-
dase deficiency. Lack of this enzyme particularly affects the
cardiorespiratory system since mechanical performance of
striated muscle is severely depressed. Skeletal muscle wast-
ing, either a result of apoptosis or disuse atrophy, substan-
tially contributes to the loss of force generation. Furthermore,
it has been hypothesised that longitudinal force transmission
inside the remaining myocytes is hampered by increased
lysosomal dimensions, cytoplasmic deposition of non-con-
tractile material and focal regions of contractile protein
degradation.
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